Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.74 |
| ▸ | TACR3 | P29371 | 18/20 | 0.74 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1871381 | 0.96 | TACR1 (0.69) | TACR1TACR3GPBAR1 | |
| SCHEMBL27642982 | 0.91 | TACR1 (0.64) | TACR1TACR3GPBAR1 | |
| SCHEMBL1873637 | 0.91 | TACR1 (0.62) | TACR1TACR3GPBAR1 | |
| SCHEMBL5782199 | 0.91 | TACR1 (0.73) | TACR1TACR3 | |
| SCHEMBL337006 | 0.91 | GPBAR1 (0.76) | TACR1TACR3GPBAR1 | |
| SCHEMBL30376925 | 0.91 | GPBAR1 (0.76) | TACR1TACR3GPBAR1 | |
| SCHEMBL1872983 | 0.90 | TACR1 (0.61) | TACR1TACR3GPBAR1 | |
| SCHEMBL5780897 | 0.90 | TACR1 (0.72) | TACR1TACR3 | |
| SCHEMBL1869830 | 0.89 | TACR1 (0.60) | TACR1TACR3GPBAR1 | |
| SCHEMBL1872916 | 0.89 | TACR1 (0.60) | TACR1TACR3GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-1643998-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013050-A1 | DUAL NK1/NK3 ANTAGONISTS AGAINST SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-6770637-B2 | N-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-6-(4-HYDROXYACETYL-PIPERAZIN-1 -YL)-N-METHYL-4-O-TOLYL-NICOTINAMIDE, FOR EXAMPLE | HOFFMANN-LA ROCHE INC. | 2004-08-03 | — | — | US | disclosed |
| EP-1309559-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | F. HOFFMAN-LA ROCHE AG (CH) | 2002-04-04 | — | — | US | disclosed |
| WO-2002016324-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | TACR1 2320/4885TACR3 3314/4885GPBAR1 1351/4885 |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | TACR1 3/4885TACR3 4/4885GPBAR1 313/4885 |
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | NPSR1, NTSR1, NTSR2 | TACR1 4/4885TACR3 15/4885GPBAR1 430/4885 |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, TAC3, TACR1 | TACR1 3/4885TACR3 4/4885GPBAR1 313/4885 |
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | TACR2, TACR1, TAC3 | TACR1 2/4885TACR3 6/4885GPBAR1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.